In reaction to strong earnings/guidance:

HDL +26.1%, QTWW +17.5%, TLCV +15.3%, MBLX +11.7%, JASO +9.4%, JCG +5.6% (also upgraded to outperform at Raymond James), AEO +4.1%, DXCM +3.7%, TTWO +2.6%, CAT +2.3%, EXLS +1.9%, STLD +1.6%... Select European financial names showing strength: UBS +3.6%, ING +3.3%, BCS +3.3%, CS +3.3%, DB +1.0%... Select solar names showing strength following JASO earnings: SOLF +2.1%, ESLR +1.8%, STP +1.7% (prices $500 mln convertible senior notes), SPWR +1.6%, AKNS +1.2%, CSIQ +1.1%... Other news: TWTI +40.8% (confirms HPV clinical trial achieves primary clinical endpoints), CRXX +20.9% (says drug candidate CRx-191 demonstrates 'positive' phase 2 results in psoriasis), DNDN +11.4% (FDA agrees to amend Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE), SIMO +7.9% (announces $40 mln stock repurchase program), FLDR +6.5% (announces a supply agreement with Lowe's), TASR +2.8% (announces United States Air Force Security Forces to deploy TASER X26 devices), CAM +2.7% (announces $650 mln contract for subsea equipment offshore West Africa), BHP +2.3%, RTP +2.2%, WWE +1.0% (Cramer makes positive comments on MadMoney)... Analyst upgrades: TMA +31.4% (upgraded to Peer Perform at Bear Sterns), DMND +4.1% (upgraded to Buy from Neutral at Piper Jaffray), ABH +2.3% (upgraded to Mkt Perform at BMO), DVA +1.3% (upgraded to Outperform at Piper Jaffray), NTY +1.2% (upgraded to Outperform at RBC), SSRX +1.1% (initiated with a Buy at Brean Murray).